Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 12/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206840 | 0.86 | MAPT (0.47) | VCAM1MAPTALDH1A1LMNARAF1 | |
| SCHEMBL1662868 | 0.85 | MAPT (0.53) | MAPTALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL14290088 | 0.84 | MAPT (0.64) | VCAM1MAPTALDH1A1LMNARAF1 | |
| SCHEMBL9513657 | 0.84 | MAPT (0.56) | VCAM1MAPTALDH1A1LMNARAF1 | |
| SCHEMBL9525782 | 0.83 | MAPK1 (0.50) | MAPTALDH1A1LMNARAF1HPGD | |
| SCHEMBL1181285 | 0.82 | ALDH1A1 (0.44) | VCAM1MAPTALDH1A1LMNARAF1 | |
| SCHEMBL14334126 | 0.81 | ALDH1A1 (0.49) | VCAM1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1173706 | 0.81 | MAPT (0.56) | MAPTALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL5465073 | 0.81 | MAPT (0.50) | MAPTALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL29960101 | 0.81 | MAPT (0.56) | MAPTALDH1A1LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| EP-1018333-B1 | Use of cationic monobenzene nitroanilines for dyeing keratin fibres , compositions and dyeing process | OREAL (FR) | 2006-03-01 | — | — | EP | disclosed |
| CN-1191051-C | Application of cation mono-benzol nitrophenylamine in keratin fiber dyeing dye composition and dyeing method | OREAL (FR) | 2005-03-02 | — | — | CN | disclosed |
| US-6478827-B1 | Use of cationic monobenzene nitroanilines in the dyeing of keratinous fibers, dyeing compositions and dyeing processes | L'ORéAL S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| CN-1267510-A | Application of cation mono-benzol nitrophenylamine in keratin fiber dyeing dye composition and dyeing method | OREAL (FR) | 2000-09-27 | — | — | CN | disclosed |
| EP-1018333-A2 | Use of cationic monobenzene nitroanilines for dyeing keratin fibres , compositions and dyeing process | L'OREAL (FR) | 2000-07-12 | — | — | EP | disclosed |
| US-5085666-A | NITROANILINES AND HAIR-DYEING COMPOSITIONS IN WHICH THEY ARE PRESENT | L'OREAL (FR) | 1992-02-04 | — | — | US | disclosed |
| US-5026401-A | Hair dyes | L'OREAL (FR) | 1991-06-25 | — | — | US | disclosed |
| US-4973757-A | Process for the preparation of nitroanilines | L'OREAL (FR) | 1990-11-27 | — | — | US | disclosed |
| US-4637821-A | HAIR, DYEING | L'OREAL (FR) | 1987-01-20 | — | — | US | disclosed |
| US-4417896-A | NITRO-,AMINO-,PHENOXYALKANOLS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-11-29 | — | — | US | disclosed |
| US-4337061-A | NITRO DYES IN AQUEOUS SOLUTION | SOCIETE ANONYME DITE: L'OREAL (FR) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | VCAM1 4865/4885MAPT 758/4885ALDH1A1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.